Communiqués BriaCell Therapeutics Corp. Nasdaq

Actions

BCTX

CA1079301091

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 05/07/2024			Varia. 5j.	Varia. 1 janv.
1,01 ^USD	+1,00 %		-11,40 %	-82,74 %

14/06	BriaCell Therapeutics Corp. annonce ses résultats pour le troisième trimestre et les neuf mois clos le 30 avril 2024	CI
03/06	Briacell Therapeutics Corp. présente des données d'efficacité clinique à l'ASCO 2024	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

BriaCell Therapeutics : NOTICE OF NO AUDITOR REVIEW OF THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS Form 8 K	14/06	PU
BriaCell Presents Clinical Efficacy Data at ASCO 2024	03/06	AQ
BriaCell Initiates Patient Enrollment in First-in-Human Study of Bria-OTS in Advanced Metastatic Breast Cancer	31/05	AQ
BriaCell Initiates Patient Enrollment in First-in-Human Study of Bria-OTS™ in Advanced Metastatic Breast Cancer	30/05	AQ
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study	28/05	AQ
BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024	24/05	AQ
BriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering	17/05	AQ
BriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering	15/05	AQ
BriaCell Announces Oral and Poster Presentations at ASCO 2024	24/04	AQ
BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer	10/04	AQ
BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR	09/04	AQ
BriaCell Therapeutics : NOTICE OF NO AUDITOR REVIEW OF THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS - Form 8-K	02/04	PU
BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies	07/03	AQ
BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference	06/03	AQ
BriaCell Provides Update on Alleged Illegal Trading of Public Securities	27/02	AQ
BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case	07/02	AQ
Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing	06/02	AQ
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting	31/01	AQ
BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with “Eye-Bulging” Metastatic Breast Cancer	04/01	AQ
BriaCell Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients	28/12	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués BriaCell Therapeutics Corp. Nasdaq

Actions

BCTX

CA1079301091

Communiqués

Filtres